Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,962 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (534)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07255872 | A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia | recruiting | Phase 2 / Phase 3 | 216 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07605949 | Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML(RAVEN) | not yet recruiting | Phase 2 | 88 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 |
| Sep 10, 2026 |
| clinicaltrials |
| NCT07623187 | A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy(EVICTION 3) | not yet recruiting | Phase 2 / Phase 3 | 540 | IpsenINDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07813390 | Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure(HLA-AML) | enrolling by invitation | Phase 2 | 73 | Guangdong Second Provincial General HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04049539 | Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction | recruiting | Phase 1 / Phase 2 | 28 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06429098 | Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML | active not recruiting | Phase 2 | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06954987 | Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | not yet recruiting | Phase 2 | 244 | National Cancer Institute (NCI)NIH | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07153497 | Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) | not yet recruiting | Phase 2 | 132 | National Cancer Institute (NCI)NIH | 0 | Sep 9, 2026 | clinicaltrials |
| NCT04269213 | CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old | completed | Phase 2 | 21 | Roswell Park Cancer InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03383575 | Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | recruiting | Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04746235 | Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia | active not recruiting | Phase 2 | 85 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05010122 | ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | recruiting | Phase 1 / Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT03013998 | Study of Biomarker-Based Treatment of Acute Myeloid Leukemia | recruiting | Phase 2 / Phase 3 | 3,000 | Beat AML, LLCOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05282459 | Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation | completed | Phase 1 / Phase 2 | 17 | Tian Yi ZhangOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04330820 | Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)(RELAX) | completed | Phase 1 / Phase 2 | 55 | Technische Universität DresdenOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05939180 | VA vs DA for Newly Diagnosed Hig-risk AML | recruiting | Phase 2 / Phase 3 | 116 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07025824 | Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation(RELEVANT) | recruiting | Phase 2 | 220 | Technische Universität DresdenOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04262843 | Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia | active not recruiting | Phase 2 | 33 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05322850 | Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) | recruiting | Phase 1 / Phase 2 | 40 | University of FloridaOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT01885689 | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 2 | 72 | City of Hope Medical CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05904106 | Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML(VINCENT) | recruiting | Phase 2 | 146 | Technische Universität DresdenOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06930352 | Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy | recruiting | Phase 2 | 70 | Uma BorateOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07163793 | Pilot Study of Reduced Venetoclax Exposure | active not recruiting | Phase 2 | 41 | Northwell HealthOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03222674 | Multi-CAR T Cell Therapy for Acute Myeloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04033302 | Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06717958 | Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation(PIVOT) | recruiting | Phase 2 | 76 | Technische Universität DresdenOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07754799 | A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia | not yet recruiting | Phase 2 | 320 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT04493164 | CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06232655 | Cladribine Venetoclax in Monocytic AML | active not recruiting | Phase 2 | 10 | University of Colorado, DenverOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06811233 | Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study | recruiting | Phase 2 | 140 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07053020 | A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) | not yet recruiting | Phase 1 / Phase 2 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04010877 | Multiple CAR-T Cell Therapy Targeting AML | terminated | Phase 1 / Phase 2 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05780879 | A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia | terminated | Phase 2 | 10 | University of Michigan Rogel Cancer CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06158828 | Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML(ABCD-NK) | recruiting | Phase 1 / Phase 2 | 68 | Washington University School of MedicineOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03728335 | Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation | suspended | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07779031 | A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT(TP53) | active not recruiting | Phase 1 / Phase 2 | 58 | Liping DouOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT02392572 | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome | terminated | Phase 1 / Phase 2 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT02835222 | Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients | active not recruiting | Phase 2 | 57 | Wake Forest University Health SciencesOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05796570 | A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies(MORE) | active not recruiting | Phase 2 | 29 | Franziska WachterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03147612 | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07770698 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Phase 1 / Phase 2 | 30 | BeOne MedicinesINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT06001385 | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis(OPTIMIZE) | active not recruiting | Phase 2 | 313 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07761533 | PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS | recruiting | Phase 1 / Phase 2 | 29 | Chaser Therapeutics, Inc.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT03737955 | Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia | recruiting | Phase 2 | 36 | University of WashingtonOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04708054 | Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | recruiting | Phase 2 / Phase 3 | 324 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04827719 | BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS | completed | Phase 2 | 38 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03503409 | IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome | active not recruiting | Phase 2 | 68 | Groupe Francophone des MyelodysplasiesOTHER | 2 | Aug 10, 2026 | clinicaltrials |
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials